Caribou Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Caribou Biosciences şirketinin kazançları yıllık ortalama -28.9% oranında azalırken, Biotechs sektörünün kazançları yıllık 24.4% oranında artan oldu. Gelirler yıllık ortalama 26% oranında artan oldu.

Anahtar bilgiler

-28.9%

Kazanç büyüme oranı

26.0%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	26.0%
Özkaynak getirisi	-58.9%
Net Marj	-1,491.9%
Son Kazanç Güncellemesi	31 Dec 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data

Jan 02

Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely

Dec 31

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Nov 05

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Sep 30

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Sep 06

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Jul 26

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Jul 03

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Jun 05

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

Apr 18

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Apr 17

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Feb 15

Caribou Biosciences: Under The Radar With Catalysts Approaching

Feb 01

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Jan 10

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Nov 18

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Feb 24

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Oct 12

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Sep 16

Caribou Biosciences: Potential To Change CAR-T Landscape

Aug 01

Crispred CAR-T Cells In The Clinic

May 19

Caribou Biosciences, Inc. (NASDAQ:CRBU) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 13

Gelir ve Gider Dağılımı

Caribou Biosciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:CRBU Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
31 Dec 24	10	-149	43
30 Sep 24	11	-148	42
30 Jun 24	33	-123	46
31 Mar 24	33	-115	44
31 Dec 23	34	-102	38
30 Sep 23	35	-95	37
30 Jun 23	14	-111	37
31 Mar 23	15	-108	37
31 Dec 22	14	-99	38
30 Sep 22	13	-91	37
30 Jun 22	13	-85	34
31 Mar 22	11	-73	29
31 Dec 21	10	-67	24
30 Sep 21	8	-63	21
30 Jun 21	5	-50	17
31 Mar 21	12	-38	15
31 Dec 20	12	-34	14
31 Dec 19	6	-23	16

Kaliteli Kazançlar: CRBU şu anda kârlı değil.

Büyüyen Kar Marjı: CRBU şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: CRBU kârlı değildir ve zararlar son 5 yılda yılda 28.9% oranında artmıştır.

Büyüme Hızlandırma: CRBU 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: CRBU kârlı olmadığından, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( 40.4% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: CRBU hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -58.95% ) sahiptir.

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/03/13 19:02
Gün Sonu Hisse Fiyatı	2025/03/13 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Caribou Biosciences, Inc. 12 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Alec Stranahan	BofA Global Research
Leah Rush Cann	Brookline Capital Markets
Rick Bienkowski	Cantor Fitzgerald & Co.

Caribou Biosciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

First quarter 2024 earnings: EPS misses analyst expectations

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Price target increased by 7.8% to US$14.29

Full year 2024 earnings: EPS in line with analyst expectations despite revenue beat

New minor risk - Market cap size

Caribou Biosciences: CB-010 And Other CAR-Ts Pressing Forward Despite Initial Data

Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer

Here's Why Caribou Biosciences (NASDAQ:CRBU) Must Use Its Cash Wisely

Robbins LLP Informs Stockholders of Caribou Biosciences, Inc. of the Class Action Lawsuit

Price target decreased by 20% to US$12.50

The Rosen Law Firm, P.A. Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Caribou Biosciences, Inc

Price target increased by 11% to US$17.29

Consensus revenue estimates decrease by 18%, EPS upgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares Bounce 25% But Its Business Still Trails The Industry

Insufficient new directors

Caribou Biosciences: CB-010, chRDNA Technology Continue To Show Promise In Gene Editing

Here's Why We're Watching Caribou Biosciences' (NASDAQ:CRBU) Cash Burn Situation

Caribou Biosciences Announces the Fda Has Granted Fast Track Designations to Cb-010 in Refractory Sle and to Cb-012 in Relapsed or Refractory Aml

Caribou Biosciences Appoints Tina Albertson as Chief Medical Officer

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Share Price Boosted 39% But Its Business Prospects Need A Lift Too

Caribou Biosciences, Inc. Appoints Terri Laufer to Its Scientific Advisory Board

Caribou Biosciences: Promising Gene Editing Therapies With Strong Buy Potential

Price target decreased by 16% to US$16.63

Little Excitement Around Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Revenues As Shares Take 43% Pounding

Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology (Asco) Annual Meeting

First quarter 2024 earnings: EPS misses analyst expectations

Caribou Biosciences, Inc., Annual General Meeting, Jun 13, 2024

Caribou Biosciences: 2 Clinical Data Updates In 2024 Could Bring Value

More Unpleasant Surprises Could Be In Store For Caribou Biosciences, Inc.'s (NASDAQ:CRBU) Shares After Tumbling 25%

Caribou Biosciences, Inc. Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus

Price target decreased by 8.0% to US$20.25

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 25% Share Price Surge Not Quite Adding Up

Chief Scientific Officer exercised options to buy US$212k worth of stock.

Caribou Biosciences: Under The Radar With Catalysts Approaching

Caribou Biosciences (NASDAQ:CRBU) Is In A Good Position To Deliver On Growth Plans

Caribou Biosciences, Inc. Appoints Tim Kelly as Chief Technology Officer

Syed Rizvi to Leave the Caribou Biosciences, Inc. as Chief Medical Officer, Effective from December 31, 2023

Caribou Biosciences, Inc.'s (NASDAQ:CRBU) 28% Price Boost Is Out Of Tune With Revenues

Consensus revenue estimates increase by 71%

Price target decreased by 7.8% to US$22.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences, Inc. Appoints Sundar Jagannath to its Scientific Advisory Board

Caribou Biosciences, Inc. Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Caribou Biosciences, Inc. Appoints Reigin Zawadzki as Chief People Officer

Consensus revenue estimates decrease by 19%, EPS upgraded

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.4% to US$24.86

Price target decreased by 8.6% to US$25.14

Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL

New minor risk - Shareholder dilution

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth

Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Caribou Biosciences, Inc

Pomerantz Law Firm Announces the Filing of A Class Action Against Caribou Biosciences, Inc

Caribou Biosciences, Inc. Appoints Jason V. O'Byrne as Principal Accounting Officer

Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy

Chief Scientific Officer exercised options to buy US$206k worth of stock.

Caribou Biosciences, Inc. Announces the FDA Granted Regenerative Medicine Advanced Therapy and Fast Track Designations to Cb-010, an Allogeneic Anti-Cd19 Car-T Cell Therapy

Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-Bcma Car-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Caribou Biosciences Presents Case Report on Long-Term Follow Up of First Patient Dosed in Phase 1 Antler Trial At the Lymphoma, Leukemia, & Myeloma Congress 2022

Caribou Biosciences: Strong Momentum Possible If Higher Dose Shows Durability

Vice President of Finance & Controller recently sold US$108k worth of stock

Insider exercised options to buy US$314k worth of stock.

Companies Like Caribou Biosciences (NASDAQ:CRBU) Are In A Position To Invest In Growth